SSA
NKGN

Schonfeld Strategic Advisors’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,085
Closed -$115K – 2406
2023
Q2 		$115K Sell
11,085
-12,215
-52% -$125K ﹤0.01% 1701
2023
Q1 		$236K Sell
23,300
-7,100
-23% -$71.6K ﹤0.01% 1472
2022
Q4 		$302K Sell
30,400
-11,100
-27% -$110K ﹤0.01% 1791
2022
Q3 		$405K Sell
41,500
-11,408
-22% -$111K ﹤0.01% 1895
2022
Q2 		$514K Buy
52,908
+408
+0.8% +$3.97K 0.01% 1348
2022
Q1 		$510K Buy
52,500
+2,500
+5% +$24.2K ﹤0.01% 1356
2021
Q4 		$484K Buy
50,000
+35,549
+246% +$346K ﹤0.01% 1281
2021
Q3 		$140K Buy
+14,451
New +$141K ﹤0.01% 1864

Other funds holding NKGN

MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AIMCA
Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $16.7B AUM 23.27% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Schonfeld Strategic Advisors's NKGN Position: Q3 2023 in Review

Schonfeld Strategic Advisors sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q3 2023, closing a stake of 11,085 shares — an estimated $115K sold.

Schonfeld Strategic Advisors first reported a position in NKGN in Q3 2021 and held it in 8 quarters. The position peaked at $514K in Q2 2022. 13 funds tracked by Wall St. Rank hold NKGN as of Q3 2023.

  • Schonfeld Strategic Advisors reported no remaining NKGen Biotech, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 11,085 NKGen Biotech, Inc. Common Stock shares in Q3 2023, an estimated $115K.
  • Schonfeld Strategic Advisors first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
  • Schonfeld Strategic Advisors's NKGen Biotech, Inc. Common Stock position peaked at $514K in Q2 2022.
  • 13 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q3 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.